Navigation Links
Celebrex-Lipitor combo may halt prostate cancer
Date:4/14/2008

NEW BRUNSWICK, N.J. Researchers at Rutgers Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.

Prostate cancer is the second leading cause of cancer death in men in the United States, with more than a quarter-million new cases appearing each year, according to the American Cancer Society. The findings are being presented by Rutgers Professor Xi Zheng at the annual meeting of the American Association for Cancer Research in San Diego, April 14th.

In the early stage of the disease, when it is typically diagnosed, prostate cancer cells depend on androgen hormones, such as testosterone, to grow. Treatment at this stage involves either decreasing the production of the hormone or blocking its actions on the cancer cells.

Anti-androgen therapy slows the prostate cancer but eventually the cancer becomes androgen-independent, the therapy becomes ineffective and the cancer cells become more aggressive, said Xi Zheng, assistant research professor at Rutgers, The State University of New Jersey, who conducted the study.

Treatments available for the later stage cancers are not very good, said Allan Conney, director of Rutgers Susan Lehman Cullman Laboratory for Cancer Research, another researcher on the project. Oncologists employ classical chemotherapy drugs which are very toxic and dont work all that well.

Zheng and Conneys research objective was to find a way to indefinitely delay the transition to androgen-independence, prolonging the time during which the cancer would be responsive to effective, low-toxicity, anti-hormone therapy.

Zheng explained that their experiments were first conducted on cell cultures in the laboratory, where the researchers tested the effects of the drugs on the growth of prostate cancer cells from four different cell lines. They then moved on to test the drugs on specially bred mice in which prostate cancer tumors were introduced under the skin. Celebrex alone, Lipitor alone, and the two in combination were tested at the lab bench and on the mice.

A combination of low doses of Lipitor and Celebrex had a more potent inhibiting effect on the formation of later stage tumors than a higher dose of either agent alone, Zheng reported. The results from our study indicate that a combination of Lipitor and Celebrex may be an effective strategy for the prevention of prostate cancer progression from the first to the second stage.

Zheng also noted that the team is exploring the underlying molecular mechanisms to understand how Lipitor and Celebrex work on prostate cancer, perhaps identifying an important signaling pathway for tumor cell growth that the drugs inhibit.

Conney pointed out that previous experiments reported in the Sept. 15, 2007, issue of Clinical Cancer Research had demonstrated that the Lipitor-Celebrex combination also inhibited the growth of prostate cancer cells in the later androgen-independent stage.

So if you can affect the early stage and prevent it from becoming the more severe form, thats a good thing. If you can also inhibit the growth of the more severe form, thats also a good thing, Conney said.

Human clinical trials are being planned at the Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey in New Brunswick.

If the clinical trials go well, we could have something available in five years, but it would be nice to speed that up, Conney said. If the trials show that the drug therapy does a good job of preventing the cancer from advancing, we wont need to worry about how to handle the more aggressive later stage cancer.

This is something we hope is going to save lives, he added.


'/>"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related medicine news :

1. Green Tea, Mushroom Extract Combo Slows Sarcomas
2. Hormone Combo May Provide Reversible Male Birth Control Tool
3. LG Electronics Debuts Unique Allergen-Reducing Steam Washer/Dryer Combo
4. Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining
5. MRI/PET scanner combo
6. Treatment Combo for Pancreatic Cancer Has Limited Benefit
7. Raised Breast Cancer Risk Persists After Combo HRT Stopped
8. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
9. Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
10. Combo Therapy Shows Promise in Treating Brain Tumors
11. Combo Treatment Best for Elderly Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Caduceus International Publishing (CIP), ... announce a new online course entitled Personal & Community Health for ... strategies for achieving optimal well-being and teaches students how to apply them in ...
(Date:6/20/2017)... ... 2017 , ... HOUSTON – Brazos Towers at Bayou Manor is proud ... options for today’s modern senior. Brazos Towers at Bayou Manor has more than 50 ... offering them the services to support that lifestyle both now and in the future. ...
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... ... ... Uniworld Boutique River Cruise Collection recently gave cruisers a chance to ... Joie de Vivre . What really sets this ship apart from the competition, however, ... enough to dock directly in Paris. With The Cruise Web’s new infographic, you can ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: